- Home
- CASI vs NSPR Comparison
CASI vs NSPR Comparison
Compare CASI & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- NSPR
- Stock Information
- Founded
- CASI 1991
- NSPR 2005
- Country
- CASI China
- NSPR Israel
- Employees
- CASI N/A
- NSPR N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- NSPR Medical/Dental Instruments
- Sector
- CASI Health Care
- NSPR Health Care
- Exchange
- CASI Nasdaq
- NSPR Nasdaq
- Market Cap
- CASI 58.8M
- NSPR 63.0M
- IPO Year
- CASI 1996
- NSPR N/A
- Fundamental
- Price
- CASI $3.09
- NSPR $2.79
- Analyst Decision
- CASI Strong Buy
- NSPR Strong Buy
- Analyst Count
- CASI 1
- NSPR 2
- Target Price
- CASI $6.00
- NSPR $4.75
- AVG Volume (30 Days)
- CASI 56.2K
- NSPR 33.6K
- Earning Date
- CASI 11-15-2024
- NSPR 11-12-2024
- Dividend Yield
- CASI N/A
- NSPR N/A
- EPS Growth
- CASI N/A
- NSPR N/A
- EPS
- CASI N/A
- NSPR N/A
- Revenue
- CASI $22,055,000.00
- NSPR $6,821,000.00
- Revenue This Year
- CASI N/A
- NSPR $13.36
- Revenue Next Year
- CASI $134.79
- NSPR $49.64
- P/E Ratio
- CASI N/A
- NSPR N/A
- Revenue Growth
- CASI N/A
- NSPR 24.70
- 52 Week Low
- CASI $2.05
- NSPR $1.81
- 52 Week High
- CASI $8.19
- NSPR $3.42
- Technical
- Relative Strength Index (RSI)
- CASI 39.70
- NSPR 44.90
- Support Level
- CASI $2.50
- NSPR $2.80
- Resistance Level
- CASI $3.47
- NSPR $2.98
- Average True Range (ATR)
- CASI 0.43
- NSPR 0.16
- MACD
- CASI 0.07
- NSPR -0.04
- Stochastic Oscillator
- CASI 39.80
- NSPR 0.00
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.